Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Protalix BioTherapeutics, Inc. (PLX)

1.08   0.01 (0.93%) 06-29 18:18
Open: 1.07 Pre. Close: 1.07
High: 1.08 Low: 1.05
Volume: 161,860 Market Cap: 51(M)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.08 - 1.09 1.09 - 1.09
Low: 1.04 - 1.04 1.04 - 1.05
Close: 1.07 - 1.08 1.08 - 1.09

Technical analysis

as of: 2022-06-29 4:56:39 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.37     One year: 1.47
Support: Support1: 1.03    Support2: 0.86
Resistance: Resistance1: 1.17    Resistance2: 1.25
Pivot: 1.08
Moving Average: MA(5): 1.09     MA(20): 1.11
MA(100): 1.08     MA(250): 1.15
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 34.9     %D(3): 33.4
RSI: RSI(14): 45.1
52-week: High: 2  Low: 0.69
Average Vol(K): 3-Month: 598 (K)  10-Days: 126 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ PLX ] has closed above bottom band by 36.2%. Bollinger Bands are 79% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 29 Jun 2022
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions -

Wed, 29 Jun 2022
Protalix BioTherapeutics (NYSE:PLX) Upgraded by to “Buy” - Defense World

Mon, 27 Jun 2022
Budget Alternatives to Technics Turntables - We Rave You

Mon, 27 Jun 2022
Laser Tracker Market Size, Scope and Forecast | Faro, On-Trak Photonics Inc., Variation Reduction Solutions API, Hexagon, PLX Inc. VMT GmbH, Hubbs Machine and Manufacturing Inc, SGS – Designer Women - Designer Women

Fri, 17 Jun 2022
Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Short Interest Update - Defense World

Tue, 14 Jun 2022
PLx Pharma Inc.'s (NASDAQ:PLXP) recent US$9.0m market cap decline means a loss of US$31k for insiders who bought this year - Simply Wall St

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 46 (M)
Shares Float 38 (M)
% Held by Insiders 17.8 (%)
% Held by Institutions 8.3 (%)
Shares Short 4,580 (K)
Shares Short P.Month 4,560 (K)

Stock Financials

EPS -0.5
EPS Est Next Qtl -0.01
EPS Est This Year -0.19
EPS Est Next Year -0.11
Book Value (p.s.) 0
Profit Margin (%) -41.7
Operating Margin (%) -24.2
Return on Assets (ttm) -9.6
Return on Equity (ttm) 0
Qtrly Rev. Growth 11.6
Gross Profit (p.s.) 1.14
Sales Per Share 1.08
EBITDA (p.s.) -0.24
Qtrly Earnings Growth 0
Operating Cash Flow -13 (M)
Levered Free Cash Flow -9 (M)

Stock Valuations

PE Ratio -2.17
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0.99
Price to Cash Flow -3.86

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.